Product involved: Mucosamin Mouthwash

Prevention of Oral Mucositis in Patients Undergoing Haematopoietic Stem Cell Transplants (HSCT)


Prevention of oral mucositis in patients undergoing haematopoietic stem cell transplants (HSCT)


3 randomised groups:

  • GROUP 1 (33 patients): use of Mucosamin Spray in case of onset of oral mucositis on lesions. Professional oral hygiene session and instructed to use Mucosamin® from the first day of admission;
  • GROUP 2 (32 patients): professional oral hygiene session and standard treatment with 0.20% Chlorhexidine mouthwash;
  • GROUP 3 (34 patients): prescribed 0.20% Chlorhexidine only;


  • WHO MUCOSITIS SCALE: 0 = no symptoms; 1 = pain, erythema; 2 = erythema, ulceration but able to eat solids; 3 = ulceration and the need for a liquid diet; 4 = oral feeding not possible
  • OMAS Mucositis: (Ulceration 0 = no lesion; 1 = lesion <1 cm2; 2 = lesion from 1 to 3 cm2; 3 = lesion> 3 cm2; Erythema 0 = none; 1 = not severe; 2 = severe)
  • PERIODONTAL PLATE: Plaque index.
  • PSR bleeding index

Development of mucositis in the patients of the 3 groups

Evaluation of Oral Mucositis in the 3 groups

Evaluation of Oral Mucositis in the 3 groups (OMAS scale)

Evaluation of  healing time of Oral Mucositis in the 3 groups

Clinical Results

• Reduction of the onset of oral mucositis.
• Reduction of the severity of oral mucositis.
• The mouthwash in prevention and the spray in treatment are a valuable therapeutic aid for oral mucositis in patients undergoing HSCT.

Other Clinical Evidence

I am a doctor

This area of the website is exclusively reserved for Health Professionals. By clicking on “Confirm”, I confirm that I am a Health Professional.